Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Stok Raporu

Piyasa değeri: US$7.7b

Jazz Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Jazz Pharmaceuticals şirketinin kazançları yıllık ortalama -10.3% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 1.2% oranında artan oldu. Gelirler yıllık ortalama 14.4% oranında artan oldu. Jazz Pharmaceuticals şirketinin öz sermaye getirisi 11.1% olup, net marjı 11.6% dir.

Anahtar bilgiler

-10.3%

Kazanç büyüme oranı

-13.3%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı14.4%
Özkaynak getirisi11.1%
Net Marj11.6%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Nov 14
We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Recent updates

Jazz Pharmaceuticals: High Uncertainty, Low Risk

Nov 18

We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Nov 14
We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Oct 22
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 16

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Gelir ve Gider Dağılımı

Jazz Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:JAZZ Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 243,9934631,376834
30 Jun 243,9103951,359869
31 Mar 243,8433311,361857
31 Dec 233,8344151,307824
30 Sep 233,794801,269782
30 Jun 233,763-871,378685
31 Mar 233,738-1561,397615
31 Dec 223,659-2241,399555
30 Sep 223,584-191,276532
30 Jun 223,481-521,222536
31 Mar 223,300-4501,291530
31 Dec 213,094-3301,399476
30 Sep 212,863-1611,326416
30 Jun 212,626401,170354
31 Mar 212,436518926306
31 Dec 202,364239880310
30 Sep 202,280179846316
30 Jun 202,217133818317
31 Mar 202,188280808295
31 Dec 192,162523762275
30 Sep 192,056609626259
30 Jun 191,988656662230
31 Mar 191,954486586224
31 Dec 181,891447625227
30 Sep 181,851520667234
30 Jun 181,793434578230
31 Mar 181,687447610214
31 Dec 171,619488544198
30 Sep 171,579372518175
30 Jun 171,541399505175
31 Mar 171,528408496174
31 Dec 161,488397480160
30 Sep 161,432363470148
30 Jun 161,399361462151
31 Mar 161,352335447139
31 Dec 151,325330433133
30 Sep 151,312328422130
30 Jun 151,278266411102
31 Mar 151,23522239994
31 Dec 141,1735840485
30 Sep 141,0813235074
30 Jun 141,0068232764
31 Mar 149238030553
31 Dec 1387221628142

Kaliteli Kazançlar: JAZZ büyük bir tek seferlik zarar ile $219.3M, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: JAZZ 'nin mevcut net kar marjları (11.6%) geçen yılın (2.1%) sinden daha yüksektir.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: JAZZ şirketinin kazançları son 5 yılda yılda 10.3% oranında azaldı.

Büyüme Hızlandırma: JAZZ 'un son bir yıldaki kazanç büyümesi ( 479.3% ) 5 yıllık ortalamasını (yıllık -10.3% ) aşıyor.

Kazançlar vs. Sektör: JAZZ geçen yılki kazanç büyümesi ( 479.3% ) Pharmaceuticals sektörünün 54.6% değerini aştı.


Özkaynak Getirisi

Yüksek ROE: JAZZ 'nin Özsermaye Getirisi ( 11.1% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin